From Adalimumab to orally administered secretory IgA: preclinical characterization of ABC-301
En palabras de los autores
Reformatting therapeutic immunoglobulin G (IgG) antibodies into secretory immunoglobulin A (sIgA) may provide an alternative architecture for mucosal drug delivery. We characterized ABC-301, a recombinant human sIgA1 incorporating the antigen-binding regions of Adalimumab, and evaluated its human tumor necrosis factor alpha (TNF) neutralization, oral activity in experimental colitis, tissue biodistribution, and susceptibility to patient-derived anti-Adalimumab antibodies. ABC-301 retained human TNF binding and functional neutralization in vitro. Its whole-molecule molar neutralization IC50 was approximately 3.3-fold lower than that of Adalimumab, a difference of approximately 1.6-fold after normalization to theoretical binding-site number. In dextran sulfate sodium (DSS)-induced colitis, oral ABC-301 attenuated colon shortening and reduced colonic inflammatory myeloid populations and tissue inflammatory biomarkers relative to untreated DSS controls. Following oral administration, iodine-125-associated radioactivity was predominantly detected in gastrointestinal compartments. In seven patient-derived anti-Adalimumab antibody preparations, ABC-301 showed reduced functional susceptibility to inhibition compared with Adalimumab. These findings provide a preclinical proof of concept for IgG-to-sIgA reformatting.
Apareció: miércoles, 18 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.